November 05, 2022

Cytiva invests USD 8 Million to expand Fast Trak center in China

By Cytiva communications
  • The expanded Fast Trak center will house Cytiva’s largest biotech training center in Asia

November 6, 2022, Shanghai, China

Cytiva, a global life sciences leader, is investing USD 8 Million to expand its Fast Trak center in Shanghai to serve Asia’s rapidly-growing biopharma industry better. The center will cover 11 000 m2 and offer comprehensive training, process design & bridge manufacturing services, customer experience, SUT innovation, and validation services to accelerate the standardization, digitalization, and scalable development of China’s biopharma industry.

Cytiva China expands Fast Trak center to better serve the regional market.

Edward Zhou, President of China, Biotechnology Group, says: “China and Asia as a whole are strategic and fast-growing markets for Cytiva. Therefore, we’re dedicated to long-term development in the region. By expanding the Fast Trak center in China, we’ll substantially increase our capacity in the region and better support our customers to deliver life-changing medicines to patients at a faster speed.”

The upgraded Fast Trak center in China will be four times as large as it is now and feature four major functions.

  • Training academy– it will host Cytiva’s largest biotech training center in the Asia Pacific region, capable of training 2000 people every year. It will also showcase Cytiva’s innovation in digital and automation, including the innovative Figurate Historian System and continuous-flow manufacturing roadmap.
  • Bioprocessing acceleration – Cytiva will expand the existing biomolecule R&D and GMP pilot manufacturing platform and use FlexFactory to accelerate the development and clinical process of innovative drugs.
  • Customer experience – it will be home to Cytiva China Online Center, which is dedicated to remote and intelligent customer services with technologies including augmented reality and the Internet of things.
  • SUT innovation & validation – the center will also house Cytiva’s first SUT center of excellence in Asia, offering new product R&D tests and validation, facilitating the industry’s application of SUT throughout the region. The validation lab is expected to accomplish 350 projects every year.
  • Automation & Digital solution – as part of its Bioprocess 4.0 strategy, Cytiva will provide demonstration services of continuous manufacturing for monoclonal antibody drugs to bring better speed and efficiency to customers.

The biomedical market in China has been growing at an incredible speed. According to McKinsey, the market value of China-originated biotech companies grew from USD 1 billion to USD 180 billion from 2016 to 20211.

Follow Cytiva on LinkedIn and Twitter.


About Cytiva

At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That’s why our nearly 10 000 associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We’re driven by their desire to achieve better flexibility, capacity, and efficiency in all facets of their work – all the way from discovery to delivery.

Learn more at

Fast Trak and FlexFactory are trademarks of Global Life Sciences USA LLC or an affiliate doing business as Cytiva.